AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Effects: Some studies have suggested that high levels of TiO2 consumption may lead to gastrointestinal disturbances such as inflammation, altered gut microbiota, and increased intestinal permeability. These effects could potentially exacerbate gastrointestinal conditions such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
Genotoxicity and Carcinogenicity: There is limited evidence suggesting that TiO2 nanoparticles may have genotoxic and carcinogenic properties, particularly when inhaled or ingested in large quantities. Animal studies have shown that TiO2 nanoparticles can induce DNA damage and oxidative stress, raising concerns about their long-term health effects, including the development of cancer.
Respiratory Effects: Inhalation of TiO2 nanoparticles, particularly in occupational settings such as manufacturing or mining, may pose risks to respiratory health. Chronic exposure to airborne TiO2 particles may lead to respiratory irritation, inflammation, and impaired lung function. Individuals with pre-existing respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD) may be particularly vulnerable to the respiratory effects of TiO2 exposure.
Immune System Effects: TiO2 nanoparticles have been shown to interact with the immune system, potentially triggering inflammatory responses and immune dysregulation. Prolonged or excessive exposure to TiO2 nanoparticles may compromise immune function and increase susceptibility to infections or autoimmune diseases.
Neurotoxicity: Some studies have suggested that TiO2 nanoparticles may have neurotoxic effects, particularly in the developing brain. Animal studies have shown that prenatal or neonatal exposure to TiO2 nanoparticles can lead to neurobehavioral abnormalities, impaired learning and memory, and alterations in brain development.
Skin Sensitization: TiO2 nanoparticles have been reported to cause skin sensitization and allergic reactions in susceptible individuals. While TiO2 is commonly used in sunscreen formulations for its UV-blocking properties, some individuals may experience skin irritation or allergic dermatitis upon topical application.
Regulatory Status: In light of safety concerns surrounding TiO2 nanoparticles, regulatory agencies such as the European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA) have conducted safety assessments and established guidelines for the acceptable use of TiO2 as a food additive. These agencies have set limits on the maximum permitted levels of TiO2 in food products to minimize potential health risks.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Increases |
species | Bacteroides uniformis | Increases |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium animalis | Reduces |
species | Bifidobacterium bifidum | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium catenulatum | Reduces |
species | Bifidobacterium longum | Reduces |
species | Bifidobacterium pseudocatenulatum | Reduces |
species | Bifidobacterium pseudolongum | Reduces |
species | Lactobacillus acidophilus | Reduces |
species | Lactobacillus crispatus | Reduces |
species | Lactobacillus gasseri | Reduces |
species | Lactobacillus helveticus | Reduces |
species | Lactobacillus jensenii | Reduces |
species | Lactobacillus johnsonii | Reduces |
species | Lactobacillus kefiranofaciens | Reduces |
species | Limosilactobacillus reuteri | Reduces |
subspecies | Bifidobacterium animalis subsp. lactis | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0 | 0 |
Acne | 0.5 | 2 | -3 |
ADHD | 1.1 | 1.9 | -0.73 |
Allergic Rhinitis (Hay Fever) | 2 | 2.4 | -0.2 |
Allergies | 5.5 | 4.6 | 0.2 |
Allergy to milk products | 2.3 | 1.9 | 0.21 |
Alopecia (Hair Loss) | 0.8 | -0.8 | |
Alzheimer's disease | 2.7 | 4.9 | -0.81 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 1.3 | 0.85 |
Ankylosing spondylitis | 2 | 3.8 | -0.9 |
Anorexia Nervosa | 0.6 | 0.6 | |
Antiphospholipid syndrome (APS) | 0.9 | -0.9 | |
Asthma | 3.6 | 4.5 | -0.25 |
Atherosclerosis | 1.8 | 1.4 | 0.29 |
Atrial fibrillation | 1.5 | 1.8 | -0.2 |
Autism | 5 | 6.3 | -0.26 |
Autoimmune Disease | 0.7 | 0.9 | -0.29 |
Barrett esophagus cancer | 0.2 | 0.6 | -2 |
benign prostatic hyperplasia | 0.2 | 0.6 | -2 |
Biofilm | 0.2 | 1.8 | -8 |
Bipolar Disorder | 1.5 | 0.9 | 0.67 |
Brain Trauma | 1 | 2.1 | -1.1 |
Cancer (General) | 1.1 | 2.1 | -0.91 |
Carcinoma | 0.8 | 0.3 | 1.67 |
Celiac Disease | 3.2 | 4.5 | -0.41 |
Cerebral Palsy | 0.8 | 1.3 | -0.63 |
Chronic Fatigue Syndrome | 2.2 | 2.3 | -0.05 |
Chronic Kidney Disease | 1.6 | 2.5 | -0.56 |
Chronic Lyme | 0.2 | 0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 2.1 | -0.5 |
Chronic Urticaria (Hives) | 0.6 | 2.1 | -2.5 |
Coagulation / Micro clot triggering bacteria | 0.6 | -0.6 | |
Cognitive Function | 1.6 | 1.8 | -0.13 |
Colorectal Cancer | 3.8 | 3.7 | 0.03 |
Constipation | 2 | -2 | |
Coronary artery disease | 0.7 | 1.5 | -1.14 |
COVID-19 | 5.2 | 7 | -0.35 |
Crohn's Disease | 3.1 | 3.8 | -0.23 |
Cushing's Syndrome (hypercortisolism) | 0.2 | 0.8 | -3 |
cystic fibrosis | 0.3 | 0.8 | -1.67 |
d-lactic acidosis (one form of brain fog) | 1.4 | 0.6 | 1.33 |
deep vein thrombosis | 0.2 | 1.2 | -5 |
Denture Wearers Oral Shifts | 0 | 1.2 | 0 |
Depression | 5.9 | 6.8 | -0.15 |
Dermatomyositis | 1 | 1.4 | -0.4 |
Eczema | 1.2 | 2.2 | -0.83 |
Endometriosis | 1.2 | 2.4 | -1 |
Eosinophilic Esophagitis | 1.5 | 0.6 | 1.5 |
Epilepsy | 2.2 | 3.6 | -0.64 |
erectile dysfunction | 0.5 | -0.5 | |
Fibromyalgia | 0.8 | 1.2 | -0.5 |
Functional constipation / chronic idiopathic constipation | 2.8 | 3.4 | -0.21 |
gallstone disease (gsd) | 0.8 | 1.2 | -0.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 2 | -1 |
Generalized anxiety disorder | 1.5 | 1.9 | -0.27 |
giant cell arteritis | 0.2 | 0.2 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 2.5 | 2.6 | -0.04 |
Graves' disease | 3 | 1 | 2 |
Gulf War Syndrome | 2.3 | 2.3 | 0 |
Halitosis | 0.8 | 0.2 | 3 |
Hashimoto's thyroiditis | 1.6 | 2.2 | -0.38 |
Heart Failure | 1.6 | 3.2 | -1 |
Hidradenitis Suppurativa | 0.5 | 1.4 | -1.8 |
High Histamine/low DAO | 0.4 | 1.4 | -2.5 |
hypercholesterolemia (High Cholesterol) | 1.3 | 0.5 | 1.6 |
hyperglycemia | 1.5 | 1.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.4 | 3.2 | -7 |
hypersomnia | 0.5 | 0.2 | 1.5 |
hypertension (High Blood Pressure | 4.3 | 5.5 | -0.28 |
Hypothyroidism | 0.8 | 1.5 | -0.88 |
Hypoxia | 0.7 | 1.3 | -0.86 |
IgA nephropathy (IgAN) | 0.6 | 2.7 | -3.5 |
Inflammatory Bowel Disease | 3.2 | 5.3 | -0.66 |
Insomnia | 4 | 2.3 | 0.74 |
Intelligence | 0.9 | -0.9 | |
Intracranial aneurysms | 0.4 | 0.6 | -0.5 |
Irritable Bowel Syndrome | 2.7 | 5.4 | -1 |
ischemic stroke | 1.4 | 0.7 | 1 |
Juvenile idiopathic arthritis | 0.5 | 0.5 | |
Liver Cirrhosis | 4 | 4.8 | -0.2 |
Long COVID | 3.4 | 5.5 | -0.62 |
Lung Cancer | 0.6 | 0 | 0 |
Lymphoma | 0.2 | 0.2 | |
Mast Cell Issues / mastitis | 0.6 | 2.9 | -3.83 |
ME/CFS with IBS | 0.2 | 0.2 | 0 |
ME/CFS without IBS | 0.2 | 0.2 | 0 |
membranous nephropathy | 0.5 | 0.5 | |
Menopause | 1.5 | 0.7 | 1.14 |
Metabolic Syndrome | 4.3 | 5.8 | -0.35 |
Mood Disorders | 6.7 | 6.4 | 0.05 |
multiple chemical sensitivity [MCS] | 0.6 | 0.6 | 0 |
Multiple Sclerosis | 1.6 | 5.1 | -2.19 |
Multiple system atrophy (MSA) | 0.4 | 1.6 | -3 |
myasthenia gravis | 0.2 | 0.2 | |
neuropathic pain | 0.8 | 0.7 | 0.14 |
Neuropathy (all types) | 2 | 1.6 | 0.25 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.3 | 1.33 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 3.9 | -0.08 |
NonCeliac Gluten Sensitivity | 0.3 | 3 | -9 |
Obesity | 5.6 | 6.6 | -0.18 |
obsessive-compulsive disorder | 1.4 | 2.6 | -0.86 |
Osteoarthritis | 1.3 | 1 | 0.3 |
Osteoporosis | 2.8 | 2.5 | 0.12 |
pancreatic cancer | 0.5 | 0.6 | -0.2 |
Parkinson's Disease | 3 | 7.2 | -1.4 |
Polycystic ovary syndrome | 2.9 | 2.6 | 0.12 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0.2 | 1 | -4 |
primary biliary cholangitis | 1 | 1 | |
Primary sclerosing cholangitis | 1.4 | 1.2 | 0.17 |
Psoriasis | 1.9 | 3.3 | -0.74 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 5.6 | -1.24 |
Rosacea | 1.8 | 1.5 | 0.2 |
Schizophrenia | 4.6 | 3.8 | 0.21 |
scoliosis | 1.1 | -1.1 | |
sensorineural hearing loss | 0.1 | 0.6 | -5 |
Sjögren syndrome | 1.5 | 0.7 | 1.14 |
Sleep Apnea | 0.3 | 0.2 | 0.5 |
Slow gastric motility / Gastroparesis | 0.5 | 1.3 | -1.6 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | 0 |
Stress / posttraumatic stress disorder | 1.4 | 1.9 | -0.36 |
Systemic Lupus Erythematosus | 1.8 | 4.8 | -1.67 |
Tic Disorder | 0.5 | 0.9 | -0.8 |
Tourette syndrome | 0.2 | 1 | -4 |
Type 1 Diabetes | 3.3 | 4 | -0.21 |
Type 2 Diabetes | 4.9 | 4.9 | 0 |
Ulcerative colitis | 3.8 | 4.8 | -0.26 |
Unhealthy Ageing | 1 | 1.1 | -0.1 |
Vitiligo | 0.8 | 1.1 | -0.38 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]